CN113995743A - 苯乙酸前药的治疗性监测方法 - Google Patents

苯乙酸前药的治疗性监测方法 Download PDF

Info

Publication number
CN113995743A
CN113995743A CN202111191403.5A CN202111191403A CN113995743A CN 113995743 A CN113995743 A CN 113995743A CN 202111191403 A CN202111191403 A CN 202111191403A CN 113995743 A CN113995743 A CN 113995743A
Authority
CN
China
Prior art keywords
paa
dose
pagn
prodrug
plasma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111191403.5A
Other languages
English (en)
Chinese (zh)
Inventor
布鲁斯·沙施米德
马苏德·默克塔拉你
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imeldica Pharmaceutical Co
Original Assignee
Imeldica Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49380684&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN113995743(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Imeldica Pharmaceutical Co filed Critical Imeldica Pharmaceutical Co
Publication of CN113995743A publication Critical patent/CN113995743A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6806—Determination of free amino acids
    • G01N33/6812—Assays for specific amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
CN202111191403.5A 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法 Pending CN113995743A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261636256P 2012-04-20 2012-04-20
US61/636,256 2012-04-20
CN201280074143.6A CN104540507A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280074143.6A Division CN104540507A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法

Publications (1)

Publication Number Publication Date
CN113995743A true CN113995743A (zh) 2022-02-01

Family

ID=49380684

Family Applications (3)

Application Number Title Priority Date Filing Date
CN202111191403.5A Pending CN113995743A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法
CN201280074143.6A Pending CN104540507A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法
CN202010449455.7A Pending CN111991383A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN201280074143.6A Pending CN104540507A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法
CN202010449455.7A Pending CN111991383A (zh) 2012-04-20 2012-09-11 苯乙酸前药的治疗性监测方法

Country Status (25)

Country Link
US (4) US9561197B2 (enExample)
EP (2) EP2846791B1 (enExample)
JP (3) JP6234436B2 (enExample)
KR (2) KR102264579B1 (enExample)
CN (3) CN113995743A (enExample)
AU (3) AU2012377389A1 (enExample)
BR (1) BR112014026138A2 (enExample)
CL (2) CL2014002807A1 (enExample)
CY (1) CY1118838T1 (enExample)
DK (1) DK2846791T3 (enExample)
EC (1) ECSP14024561A (enExample)
ES (2) ES2623470T3 (enExample)
HR (1) HRP20170651T1 (enExample)
HU (1) HUE032726T2 (enExample)
IL (2) IL235127A (enExample)
LT (1) LT2846791T (enExample)
MX (1) MX365302B (enExample)
PL (1) PL2846791T3 (enExample)
PT (1) PT2846791T (enExample)
RS (1) RS55870B1 (enExample)
SG (2) SG10201608749UA (enExample)
SI (1) SI2846791T1 (enExample)
SM (1) SMT201700219T1 (enExample)
WO (1) WO2013158145A1 (enExample)
ZA (1) ZA201407597B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
BR112014026138A2 (pt) 2012-04-20 2017-06-27 Hyperion Therapeutics Inc métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético
HUE036133T2 (hu) 2012-11-21 2018-06-28 Horizon Therapeutics Llc Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére
PL2986325T3 (pl) 2013-10-14 2020-03-31 Immedica Pharma Ab Sposoby leczenia zaburzenia cyklu mocznikowego
ES2748294T3 (es) * 2014-06-04 2020-03-16 Immedica Pharma Ab Métodos para tratar trastornos del ciclo de la urea con el fin de prevenir crisis hiperamonémicas controlando los niveles de amoniaco en sangre
US9914692B2 (en) 2016-05-25 2018-03-13 Horizon Therapeutics, Llc Procedure for the preparation of 4-phenyl butyrate and uses thereof
US20190076383A1 (en) * 2017-09-08 2019-03-14 Horizon Therapeutics, Llc Methods for treating urea cycle disorders
US10668040B2 (en) 2017-09-11 2020-06-02 Horizon Therapeutics, Llc Treatment of urea cycle disorders in neonates and infants

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4284647A (en) 1980-03-31 1981-08-18 The Johns Hopkins University Process for waste nitrogen removal
US4457942A (en) 1982-08-20 1984-07-03 Brusilow Saul W Process for waste nitrogen removal
US5635532A (en) 1991-10-21 1997-06-03 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Compositions and methods for therapy and prevention of pathologies including cancer, AIDS and anemia
US5879657A (en) 1993-03-30 1999-03-09 The Dupont Merck Pharmaceutical Company Radiolabeled platelet GPIIb/IIIa receptor antagonists as imaging agents for the diagnosis of thromboembolic disorders
WO1996024571A1 (en) 1995-02-07 1996-08-15 Brusilow Saul W Triglycerides and ethyl esters of phenylalkanoic acid and phenylalkenoic acid useful in treatment of various disorders
US6219567B1 (en) 1999-06-21 2001-04-17 Cardiox Corporation Monitoring of total ammoniacal concentration in blood
US20030195255A1 (en) 2002-04-12 2003-10-16 Summar Marshall L. Method for treating hepatic encephalopathies
US20040229948A1 (en) 2002-04-12 2004-11-18 Summar Marshall L. Method for preventing hepatic encephalopathic episodes
US20050273359A1 (en) 2004-06-03 2005-12-08 Young David E System and method of evaluating preoperative medical care and determining recommended tests based on patient health history and medical condition and nature of surgical procedure
PT2319581E (pt) 2004-11-26 2015-06-30 Ucl Business Plc Composições compreendendo ornitina e fenilacetato ou fenilbutirato para tratamento de encefalopatia hepática
US20060135612A1 (en) 2004-12-17 2006-06-22 U.S. Department Of Veterans Affairs Method of ameliorating or abrogating the effects of a neurodegenerative disorder, such as amyotrophic lateral sclerosis (ALS), by using a HDAC inhibiting agent
US20070004805A1 (en) 2005-07-01 2007-01-04 Navinta Llc Process for preparation of liquid dosage form containing sodium 4-phenylbutyrate
US20100016207A1 (en) 2005-11-10 2010-01-21 Wurtman Richard J Methods and Compositions for Raising Levels and Release of Gamma Aminobutyric Acid
US8094521B2 (en) 2007-02-28 2012-01-10 Nightingale Products LLC Caregiver personal alert device
GB2451259B (en) * 2007-07-25 2011-07-20 Gp Acoustics Loudspeaker
US9078864B2 (en) 2008-01-08 2015-07-14 Akthelia Pharmaceuticals Agonists for antimicrobial peptide systems
GB2465250B (en) * 2008-08-29 2011-01-26 Ucyclyd Pharma Inc Dosing and monitoring patients on nitrogen-scavenging drugs
WO2009134460A1 (en) * 2008-04-29 2009-11-05 Hyperion Therapeutics Methods of treatment using ammonia-scavenging drugs
JP5577341B2 (ja) * 2008-08-29 2014-08-20 ハイペリオン セラピューティクス， インコーポレイテッド アンモニア捕捉薬を使用する処置方法
CN102481269B (zh) * 2009-05-11 2015-10-07 博格有限责任公司 包含辅酶q10的药物组合物及其制备方法
EP2954780A1 (en) 2009-07-24 2015-12-16 Baylor College Of Medicine Methods of modulation of branched chain acids and uses thereof
JP6049619B2 (ja) 2010-08-31 2016-12-21 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル ナノヒドロキシアパタイトを含む多孔質多糖足場、及び骨形成のための使用
EP3263102A1 (en) 2011-09-30 2018-01-03 Horizon Therapeutics, LLC Methods of therapeutic monitoring of nitrogen scavenging drugs
BR112014026138A2 (pt) * 2012-04-20 2017-06-27 Hyperion Therapeutics Inc métodos de monitoramento terapêutico de pró-fármacos de ácido fenilacético
HUE036133T2 (hu) 2012-11-21 2018-06-28 Horizon Therapeutics Llc Eljárások hepatikus enkefalopátia kezelésére szolgáló nitrogénelvonó gyógyszerek beadására és értékelésére

Also Published As

Publication number Publication date
ECSP14024561A (es) 2015-09-30
PT2846791T (pt) 2017-05-25
EP2846791B1 (en) 2017-02-08
JP6234436B2 (ja) 2017-11-22
CN104540507A (zh) 2015-04-22
CL2017001375A1 (es) 2018-01-05
PL2846791T3 (pl) 2017-07-31
EP3222275B1 (en) 2020-06-24
AU2019201811B2 (en) 2020-07-09
DK2846791T3 (en) 2017-03-27
EP2846791A4 (en) 2015-08-19
JP6637941B2 (ja) 2020-01-29
JP2015514757A (ja) 2015-05-21
KR20150013170A (ko) 2015-02-04
ES2623470T3 (es) 2017-07-11
HK1243959A1 (en) 2018-07-27
AU2012377389A1 (en) 2014-10-30
EP2846791A1 (en) 2015-03-18
MX2014012694A (es) 2015-06-03
ZA201407597B (en) 2017-05-31
RS55870B1 (sr) 2017-08-31
CL2014002807A1 (es) 2015-02-27
WO2013158145A1 (en) 2013-10-24
AU2018200163B2 (en) 2018-12-20
HK1208380A1 (en) 2016-03-04
US9561197B2 (en) 2017-02-07
US20180263938A1 (en) 2018-09-20
SMT201700219T1 (it) 2017-05-08
SI2846791T1 (sl) 2017-06-30
HRP20170651T1 (hr) 2017-06-30
JP2018039830A (ja) 2018-03-15
US20180015058A1 (en) 2018-01-18
KR102264579B1 (ko) 2021-06-11
AU2019201811A1 (en) 2019-04-04
BR112014026138A2 (pt) 2017-06-27
AU2018200163A1 (en) 2018-02-01
EP3222275A1 (en) 2017-09-27
US20130281530A1 (en) 2013-10-24
HUE032726T2 (en) 2017-10-30
US20170266143A1 (en) 2017-09-21
IL255918A (en) 2018-01-31
CY1118838T1 (el) 2018-01-10
JP2019219413A (ja) 2019-12-26
WO2013158145A9 (en) 2014-05-01
LT2846791T (lt) 2017-04-10
CN111991383A (zh) 2020-11-27
SG10201608749UA (en) 2016-12-29
IL235127A (en) 2017-12-31
KR20190116552A (ko) 2019-10-14
SG11201406745VA (en) 2014-12-30
IL255918B (en) 2019-06-30
ES2807951T3 (es) 2021-02-24
MX365302B (es) 2019-05-29

Similar Documents

Publication Publication Date Title
AU2019201811B2 (en) Methods of therapeutic monitoring of phenylacetic acid prodrugs
US10045959B1 (en) Methods of therapeutic monitoring of nitrogen scavenging drugs
US9289406B2 (en) Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy
HK1243959B (en) Methods of therapeutic monitoring of phenylacetic acid prodrugs
HK1208380B (en) Hpn-100 for use in the treatment of nitrogen retention disorders
HK1213778B (en) Methods of administering and evaluating nitrogen scavenging drugs for the treatment of hepatic encephalopathy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination